Researchers have developed a miniaturized solid-phase extraction cartridge that uses controlled pore glass and ...

QIAGEN is also introducing the QIAGEN Discovery Platform, which enables the integration of AI with QIAGEN’s biomedical knowledge base and molecular data to support drug discovery. The platform is ...

QIAGEN is also introducing the QIAGEN Discovery Platform, which enables the integration of AI with QIAGEN’s biomedical ...

The Qatra Genomic DNA Extraction Lab Kit (RUO) is the first product to emerge from Qurin's broader Qatra R&D Program, which is dedicated to developing technologies for the capture and extraction of ...

QIAGEN launched QIAmini on September 24, 2026. Qiagen stock costs EUR 39.85 in weekend trading on October 3, 2026 versus EUR ...

Automation, enzymatic synthesis and integrated services can cut costs, speed turnaround and capture demand from RNA therapeutics, NGS and CRISPR.Dublin, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ...

Qiagen launched QIAmini on September 24, 2026, and Qiagen stock was last at EUR 39.16 on the Frankfurt Stock Exchange on ...

A federal judge agreed with the plaintiffs that the disclosure of their DNA profiles to law enforcement against their wishes was a substantial invasion of their privacy.

RNA fusions offer new drug targets and insights into disease mechanisms, but detecting them is difficult. Workflows that integrate different types of samples and analyses can help.

With the addition of the QIAstat-Dx BCID GN Plus AMR Panel, QIAGEN now offers U.S. laboratories two complementary bloodstream infection panels covering gram-negative bacteria, gram-positive bacteria, ...

The new QIAstat-Dx BCID GN Plus AMR Panel identifies 13 gram-negative bacterial pathogen targets and 18 antimicrobial ...